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The  safety  of  krill  oil  was  assessed  in  a subchronic  toxicity  study  and  in a genotoxicity
test.  In a 13-week  study,  rats  were  fed  krill  oil  or control  diets. There  were  no  differences
noted  in body  weight,  food  consumption  or in the  functional  observation  battery  parame-
ters in  either  gender.  Differences  in  both  haematology  and  clinical  chemistry  values  were
noted in  the  krill  oil-treated  groups.  However  these ﬁndings  were  of no toxicological  signif-
icance.  Signiﬁcant  decreases  in absolute  and  covariant  heart  weight  in some  krill  oil-treated
animals  were  noted  although  no  corresponding  histological  changes  were  observed.  In  addi-
tion, periportal  microvesicular  hepatocyte  vacuolation  was  noted  histologically  in males
fed 5%  krill  oil.  This ﬁnding  was  not  associated  with  other  indications  of  hepatic  dysfunc-Eicosapentaenoic acid
Docosahexaenoic  acid
Astaxanthin
tion.  Given  that the  effects  of the  13-week  toxicity  study  were  non-toxic  in  nature,  the  no
observed  adverse  effect  level  (NOAEL)  for the  conditions  of  this  study  was  considered  to
be 5%  krill oil.  The  genotoxicity  experiments  documented  no mutagenicity  of  krill  oil  in
bacteria.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The beneﬁcial effects of long-chain omega-3 polyun-
saturated fatty acids (PUFAs), eicosapentaenoic acid (EPA,
20:5)  and docosahexaenoic acid (DHA, 22:6), which are
present  in fatty ﬁsh and omega-3 supplements like ﬁsh
oil,  have been well documented. Omega-3 fatty acids have
been  demonstrated to reduce plasma lipids [1], reduce
blood pressure [2], prevent arrhythmias [3] and reduce
platelet aggregation [4]. In addition to the positive effects of
Abbreviations: ANOVA, analysis of variance; DHA, docosahexaenoic
acid; EPA, eicosapentaenoic acid; FOB, functional observation battery; KO,
krill  oil; NOAEL, no observed adverse effect level; SO, soya bean oil.
∗ Corresponding author. Tel.: +47 24 13 00 00; fax: +47 24 13 01 10.
E-mail  addresses: bruce.robertson@crl.com
(B. Robertson), lena.burri@akerbiomarine.com (L. Burri),
kjetil.berge@akerbiomarine.com (K. Berge).
http://dx.doi.org/10.1016/j.toxrep.2014.07.007
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open ac
licenses/by-nc-nd/3.0/).omega-3 fatty acids demonstrated for cardiovascular dis-
ease  [5], studies also suggest that these long-chain fatty
acids  are important for immune function, bone-turnover,
insulin sensitivity and cognitive function, amongst many
other  physiological functions and their general importance
for  body composition homeostasis [6–8].
Hence the European Food Safety Authority (EFSA)
allows for health claims for 250 mg/day EPA + DHA  to con-
tribute  on normal function of the heart, for either 2 g/day
DHA  or 2 g/day EPA + DHA on maintenance of normal blood
triglyceride levels and for 3 g EPA + DHA on maintenance
of normal blood pressure. Moreover, EFSA has established
health claims on food containing at least 82.5 mg  choline
per  100 g. The choline nutrition claim covers maintenance
of normal liver function, lipid metabolism and homocys-
teine metabolism.
The  short-chain omega-3 fatty acid -linolenic acid
(ALA) is produced by plants, but in humans the enzymatic
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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Table 1
Fatty acid composition of krill oil mixed into the diets fed to Wistar rats
for 13 weeks.
Fatty acid Common name Krill oila
14:0 Myristic acid 6.4
16:0 Palmitic acid 13.6
18:0 Stearic acid 0.6
20:0 Eicosanoic acid nd
22:0 Docosanoic acid nd
16:1 n-7 Palmitoleic acid 2.5
18:1 (n-9) + (n-7) + (n-5) Elaidic acid 10.6
20:1 (n-9) + (n-7) Eicosenoic acid 0.5
22:1 (n-11) + (n-9) + (n-7) 11-docosenoic acid 0.2
24:1 n-9 Nervonic acid nd
16:2 n-4 Hexadecadienoic acid 0.3
16:3 n-4 Hexadecatrienoic acid 0.4
18:2 n-6 Linoleic acid 1.3
18:3 n-6 -Linoleic acid 0.1
20:2 n-6 Eicosadienoic acid 0.1
20:3 n-6 Dihomo--linolenic
acid
nd
20:4  n-6 Arachidonic acid 0.3
22:4 n-6 Adrenic acid nd
18:3 n-3 -Linolenic acid 1.2
18:4 n-3 Stearidonic acid 2.9
20:3 n-3 Eicosatrienoic acid 0.1
20:4 n-3 Eicosatetraenoic acid 0.4
20:5 n-3 Eicosapentaenoic acid
(EPA)
12.8
21:5  n-3 Heneicosapentenoic
acid
0.3
22:5  n-3 Docosapentaenoic acid 0.4
22:6 n-3 Docosahexaenoic acid 7.4B. Robertson et al. / Toxic
onversion efﬁciency to the longer chain PUFAs, EPA and
HA,  is rather low [9]. Phytoplankton has the ability to
onvert  ALA to EPA and DHA and by feeding on phytoplank-
on these PUFAs are enriched over the aquatic food chain.
herefore omega-3 PUFAs are found in high quantities in
.g.  krill, ﬁsh and marine mammals.
Krill are shrimp-like crustaceans mostly found in the
rctic and Antarctic oceans [10]. They are abundant and
nderutilised in the food industry and are characterised
y large energy stores. Most omega-3 supplements sold in
oday’s  market contain EPA and DHA in the form of tri-
lycerides (ﬁsh oil) or as ethyl-esters. However, in nature,
mega-3 fatty acids are also present as fatty acyl-chains
n phospholipids. In krill oil produced from Antarctic krill
Euphausia superba) a high proportion of the omega-3
atty acids are present in this molecular form [11]. More
peciﬁcally, the phospholipids mainly consist of phos-
hatidylcholines, making krill an excellent natural source
f  omega-3 containing phosphatidylcholine [12]. Several
nimal studies have demonstrated that phospholipids
hemselves, and in particular phosphatidylcholine [13–15],
ave  beneﬁcial effects on the hepatic lipid metabolism
nd might have a potential to affect cardiovascular disease
reviewed in [16]). It was also shown that the tissue uptake
f  omega-3 PUFAs is improved, when they are provided in
he  form of phospholipids instead of triglycerides [11].
In  addition to the high presence of phospholipids, krill
lso  contains the red antioxidant molecule astaxanthin
17]. The presence of astaxanthin in krill oil contributes to
he  stability of the omega-3 PUFAs in krill oil [18–21], and
ives  it the characteristic dark red colour.
To the best of our knowledge, there is no publication
escribing the safety of krill oil in genotoxicity studies.
herefore, a 13-week study in Wistar rats assessing sub-
hronic  toxicity and an Ames test to investigate potential
utagenic activity of krill oil was performed.
. Materials and methods
.1.  Test materials
SuperbaTM krill oil was supplied by Aker BioMarine
ntarctic AS, Oslo, Norway. The raw materials were
ssayed (Noﬁma Ingredients, Bergen, Norway) for ele-
ental  composition, chemical characteristics, and fatty
cid  composition and met  previously set speciﬁcations
Table 1).
.2.  Subchronic toxicity study
The design and conduct of the subchronic toxicity study
as  performed based on the regulatory guidelines OECD
o.408, OPPTS 870.3100 and US FDA Redbook.
.2.1. Animals
The  study was performed at Charles River, Tranent,
dinburgh, UK. Forty male and forty female Han Wistar
ats  were received from Charles River UK Limited and were
cclimatised for a period of 14 days. At study start, the
nimals were approximately 7 weeks old with male ani-
als  in the weight range of 179–229 g and females ofn-3  (DHA)
a g/100 g oil. nd = not detected. Lower detection limit for fatty acid mea-
surements was 0.1 g/100 g.
109–162 g. Animals were allocated to cages on racks sepa-
rated  by sex and treatment group. All animals were housed
in  the same room, but the control animals were placed
on  a separate rack. Two  to three animals were housed per
cage  in suspended polycarbonate cages. For environmental
enrichment, each cage of rats was provided wooden chew
sticks  (Tapvei Estonia OÜ, Harjumma, Estonia). Rats were
provided food and water (domestic mains water) ad libi-
tum  during this period. During the study the animals were
kept  at 19–23 ◦C, 40–70% humidity and a ﬁxed light cycle
(light hours were 0700–1900 h). Studies were conducted
in  accordance with the OECD Principles of Good Laboratory
Practice as incorporated into the United Kingdom Statutory
Instrument for GLP, and as accepted by regulatory author-
ities  throughout the European Community, United States
(FDA  and EPA) and Japan (MHLW, MAFF and METI).
2.2.2. Animal treatment
Four  groups of 10 male and 10 female Han Wistar rats
were  fed diets supplemented with a total of 8% oil. Diets
were  incorporated with 8% soya bean oil (8% SO), 1.7 (1.7%
KO,  6.3% SO), 3.3 (3.3% KO, 4.7% SO) and 5% krill oil (5% KO,
3%  SO) for a period of 13 weeks. The high dose of krill oil
corresponded to 2.5 g to 5 g/kg of body weight. After con-
version to human equivalent doses (HED), the studied dose
range  provides a 24- to 48-fold safety margin with the rec-
ommended supplement level of 1 g/day. The diets are based
on  the standard RM1  diet and were prepared by Special Diet
Services  (Witham, UK) according to their in-house standard
ology Re766 B. Robertson et al. / Toxic
operating procedures. The exact description of the RM1  diet
is  given at: http://www.sdsdiets.com/pdfs/RM1P-E-FG.pdf.
Since  the RM1  diet contained 3% soya bean oil, and 5% krill
oil  was added on top in the high dose group, the fat content
of  the control group had to be adjusted by the addition of
5%  soya bean oil. This assured similar calorie content in all
4  diets.
The prepared diets were stored frozen at −20 ◦C,
thawed, and given to the animals on a daily discard and
top-up routine. The diets were veriﬁed for stability and
homogeneity by Noﬁma AS (Bergen, Norway). After inclu-
sion  of krill oil into the ﬁnal diet form, the recovery of EPA
and  DHA was: EPA: 98.2, 97.5 and 96.1%; DHA: 97.1, 96.5
and  95.5%, in the 1.7, 3.3 and 5% krill oil diets, respec-
tively. The homogeneity was veriﬁed by measuring EPA
and  DHA in 3 samples of each of the 3 krill oil diets. The
standard deviation of EPA and DHA measured in the 3 krill
oil  diets was always less than 3.6%. All measurements were
performed at the beginning of the study.
2.2.3. Animal observations
Well-being  of the animals was monitored daily and once
each  week, all animals received a detailed clinical exami-
nation. Moreover, the animals’ eyes were examined before,
during  and at the end of the experiment.
Additionally, speciﬁc clinical observations were
recorded each day throughout the treatment period to
examine  for reaction to treatment. Body weights were
recorded once during pre-trial, then weekly through-
out the treatment. The quantity of food consumed by
each  cage of animals was measured and recorded daily
throughout pre-trial and treatment period and are given
as  g/animal/day for all weeks. Water consumption was
qualitatively evaluated by visual inspection on a weekly
basis.
At  the end of treatment period (week 12/13), detailed
neurotoxicological observations were made of all animals,
including parameters of a Functional Observation Battery
(FOB).  Most of the assessments were based on scaled
observations of the animals’ behaviour/status and included
home  cage and open ﬁeld evaluations. In addition, ease
of  removal from cage, body temperature, condition of the
eyes,  condition of the coat, presence of salivation and
overall ease of handling were recorded. Open ﬁeld obser-
vations in a standardised arena (2 min  observation period)
included latency, level of mobility, rearing, grooming, uri-
nation/defecation, arousal, posture, tremor/convulsions,
vocalisation, piloerection, palpebral closure, gait abnor-
malities, stereotypy and/or unusual behaviours. Additional
functional tests were performed at an approximately stan-
dardised  time of day (reaction to sound and reaction to
touching the rump with a blunt probe). Quantitative mea-
surements including grip strength (using a method derived
from  Meyer et al. [22]), pain perception (using a method
derived from D’Amour and Smith [30]), landing foot splay
and  motor activity.2.2.4.  Haematology, coagulation and clinical chemistry
Blood samples for haematology, coagulation and clin-
ical  chemistry were obtained from all surviving animals
via  the orbital sinus under isoﬂurane anaesthesia on theports 1 (2014) 764–776
morning  of necropsy. The animals were not deprived of
food  overnight prior to sampling. Approximately 0.5 mL of
whole  blood was transferred into tubes containing EDTA for
measurement of haematology parameters using the ADVIA
120  automated haematology analyser (Bayer, Munich,
Germany). Haemoglobin, red blood cell count, haemat-
ocrit, white blood cell count, mean cell volume, mean
cell  haemoglobin concentration, platelet count, reticulo-
cytes, neutrophils, lymphocytes, monocytes, eosinophils,
basophils and large unclassiﬁed cells were all quanti-
ﬁed. In trisodium citrate-treated blood (with a blood to
citrate  ratio of 9:1), prothrombin time and activated partial
thromboplastin time were measured with an ACL Advance
coagulation analyser (Diamond Diagnostics, MA,  USA). A
blood  ﬁlm smear was  made from all EDTA haematology
samples and stained for possible examination.
Blood collected for clinical chemistry was taken into
lithium heparin tubes, centrifuged and analysed with a
Roche  P module clinical chemistry analyser using a Roche
test  kit (Roche, Basel, Switzerland) for urea, glucose, aspar-
tate  aminotransferase, alanine aminotransferase, alkaline
phosphatase, total protein, albumin, cholesterol, total
bilirubin, calcium and phosphate. Sodium and potassium
was  analysed using Roche P module clinical chem-
istry analyser using indirect Ion Selective Electrode.
Globulin was calculated by subtraction of the albumin
concentration from the total protein concentration; albu-
min:globulin ratio was calculated by (albumin)/(total
protein − albumin).
2.2.5. Urinalysis
Urine samples were collected over a 4-h period from all
animals  during week 13. The animals were housed indi-
vidually in metabolic cages and were deprived of food and
water.  For fresh urine, the following parameters were eval-
uated:  volume (weighing of urine sample), speciﬁc gravity
(manual assessment using a refractometer), colour, pH,
protein,  glucose, ketones, urobilinogen, bilirubin, pigments
(Aution JET 9UB test strips measured using an Aution Jet
AJ4270  analyser, Menarini Diagnostics, Florence, Italy) and
microscopy  of the spun deposits (epithelial cells, crystals,
white blood cells, red blood cells, organisms, casts, other
abnormalities).
2.2.6.  Necropsy and histopathology
After 13 weeks of treatment all animals were sacriﬁced
in a random order by exsanguination after anaesthesia (car-
bon  dioxide). The animals were non-fasted to minimise
stress due to food deprivation. Terminal body weight of
each  animal was recorded, followed by severance of major
blood  vessels. All animals in the 4 different groups were
subjected to a detailed necropsy examination. In addition,
more  than 40 different tissues from the control group and
animals  given 5% krill oil were subject to a more compre-
hensive histopathological examination.
A complete external and internal examination, which
included body oriﬁces, respiratory tract and cranial,
thoracic and abdominal cavities, was performed. Represen-
tative tissues were taken from all animals and ﬁxed in 10%
neutral  buffered formalin or Davidson’s ﬂuid (only eyes,
optic  nerve and testis): abnormal tissue, adrenal glands,
ology Re
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ortic arch, blood smear, brain, eyes, epididymis, gastro-
ntestinal tract, harderian gland, heart, implant, kidney
nd  ureter, liver, lung, mesenteric lymph node, nasal cav-
ty,  oesophagus, optic nerve, ovaries, pancreas, pituitary,
rostate, rib, salivary glands, sciatic nerve, seminal vesicles,
pinal  cord, skin and mammary gland, spleen, sternum,
ubmandibular lymph node, testis, thigh muscle, thyroid
ith  parathyroid, tongue, trachea, urinary bladder, thy-
us,  uterus and vagina. Sections were cut 4–6 m thick,
nd stained with haematoxylin and eosin (H&E) (unless
therwise stated) and evaluated by a pathologist.
The following organs were weighed: adrenal glands,
rain, epididymides, heart, kidneys, liver, lung, ovaries,
ituitary gland, prostate, spleen, testes, thymus and thy-
oid.
.2.7.  Data analysis
Unless  otherwise stated, all statistical tests were two-
ided and performed at the 5% signiﬁcance level using
n-house software and performed as described below. Pair-
ise  comparisons were performed between the different
oses of krill oil and the control group for males and
emales separately. Quantitative data, body weight, food
onsumption, haematology, coagulation, clinical chemistry
nd  selected urinalysis, motor activity and quantitative
OB measurements were analysed for homogeneity of vari-
nce  using the ‘F-Max’ test. If the group variances appeared
omogeneous, a parametric ANOVA was used and pairwise
omparisons made using Fisher’s F protected LSD method
ia  Student’s t-test i.e. pairwise comparisons were made
nly  if the overall F-test was signiﬁcant. If the variances
ere heterogeneous, log or square root transformations
ere used in an attempt to stabilise the variances. If the
ariances remained heterogeneous, then a Kruskal–Wallis
on-parametric ANOVA was used and pairwise compar-
sons made using chi squared protection (via z tests,
he non-parametric equivalent of Student’s t-test). Organ
eights were analysed using ANOVA as above and by
nalysis of covariance (ANCOVA) using terminal kill body
eight  as covariate. In addition, organ weights as a percent-
ge  of terminal body weight were analysed using ANOVA
s  above. Histological incidence data were analysed using
isher’s  Exact Probability Test.
.3. Genotoxicity studies
Studies  were conducted in accordance with the OECD
rinciples of Good Laboratory Practice as incorporated into
he  United Kingdom Statutory Instrument for GLP.
.3.1. Dose-ﬁnding toxicity test for Ames assay
First, a toxicity test was performed as an initial dose-
nding test to establish suitable exposure levels for the
mes  test. The Salmonella typhimurium strain TA100 was
sed  to test toxicity of different doses of krill oil (up
o  5000 g per plate) in the presence and absence of
etabolic activation (S9 mix). The S9-based metabolic acti-
ation  system is described in more detail by [23]. The
9  enzymes used in the experiment (supernatant post-
itochondrial fraction obtained after centrifugation at
000  g) were prepared in-house from the livers of Aroclorports 1 (2014) 764–776 767
1254-treated adult, male Fischer rats, as described by Ames
et  al. [24]. The method used for the toxicity test was  simi-
lar  to the ‘Direct plate incorporation method’ used for the
Ames  test described below.
2.3.2.  Ames assay
Krill  oil was assayed for mutagenic activity using the
Ames test [24], a well-established assay for reverse muta-
tions  in amino acid-requiring strains of S. typhimurium
(his−) and Escherichia coli (trp−). Four strains of S.
typhimurium, TA1535, TA100, TA1537 and TA98 (obtained
in  1976 from Professor B.N. Ames, Department of Biochem-
istry,  University of California, USA) and one strain of E. coli,
WP2uvrA  (obtained in 1976 from the National Collection of
Industrial  Bacteria, Aberdeen, Scotland) were used.
Two  mutation experiments were performed using the
ﬁve  bacteria strains. The ﬁrst experiment was performed
by the ‘Direct plate incorporation method’ (2 mL  top agar,
0.5  mL  S9 mix  or 0.05 M phosphate buffer (pH 7.4), 0.1 mL
bacterial  culture and 0.05 mL  test item or ethanol are
thoroughly mixed and immediately poured onto minimal
medium plates) while the second was performed by the
‘Pre-incubation method’ (S9 or 0.05 M phosphate buffer,
bacteria and test item or control material (as before) are
placed  in a shaking incubator 37 ◦C for 20 min, then 2 mL
of  soft agar added and mixed and poured onto minimal
medium plates). Both tests were performed in triplicate
plates in the presence and absence of S9 mix  (S9 mixed
1:9 with the co-factors required for mixed-function oxi-
dase  activity: NADP, G-6-P, MgCl2 and KCl). Just before use,
the  test substance was dissolved and diluted in ethanol.
The  same concentration of ethanol was also added to
the  control groups. Six concentrations of krill oil were
tested: 17, 50, 167, 500, 1667 and 5000 g per plate, and
positive control chemicals were included in each experi-
ment  (2-aminoanthracene, sodium azide, 9-aminoacridine,
2-nitroﬂuorene and N-ethyl-N-nitro-N-nitrosoguanadine).
The highest concentration represents the predetermined
maximum, as recommended by relevant guidelines (OECD
guideline 471, the European Commission Annex V Text
Method B13 and B14, ICH Guidelines CPMP/ICH/141/95 and
CPMP/ICH/174/95 and USA EPA 712-C-98-247).
Following incubation at 37 ◦C for 2–3 days, the number
of his+ and trp+ revertants were counted using an electronic
image capture system (Perceptive Instruments’ Sorcerer
Colony Counter). Plates were also examined microscopi-
cally for precipitates and for micro-colony growth.
3. Results
3.1. Subchronic toxicity study
Mortality. There was  one male animal belonging to
the  control group sacriﬁced prematurely during the
study. This animal was euthanised on Day 81 of the
study having previously displayed clinical observations
including a subcutaneous mass on left ventral abdomen,
abnormal respiration, weight loss and abnormally pale fae-
ces.  Histologically, a mammary adenoma was observed,
which accounted for the subcutaneous mass observed at
necropsy.
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Table 2
Feeding (% krill oil in feed).
Week
−1 1 2 3 4 5 6 7 8 9 10 11 12 13
Males
Control 18.4 ± 0.4 20.4 ± 0.7 21.2 ± 0.4 21.3 ± 1.1 21.5 ± 1.0 22.6 ± 0.8 22.7 ± 0.5 22.3 ± 0.9 22.4 ± 0.8 22.2 ± 0.4 21.7 ± 1.0 20.8 ± 2.0 20.8 ± 2.2 19.8 ± 1.1
1.7%KO  18.1 ± 0.6 21.6 ± 0.5 21.6 ± 0.7 22.6 ± 0.9 22.7 ± 1.0 23.1 ± 1.1 22.9 ± 1.3 22.3 ± 0.6 22.1 ± 1.0 22.9 ± 0.6 21.4 ± 0.3 21.4 ± 0.5 21.7 ± 0.9 21.4 ± 1.1
3.3%KO  18.2 ± 0.5 20.0 ± 1.0 20.6 ± 1.3 20.1 ± 1.7 20.8 ± 0.9 20.4 ± 0.9 20.3 ± 0.8 19.8b ± 1.0 20.6 ± 1.4 21.0 ± 1.8 19.7 ± 1.5 19.7 ± 1.5 18.8 ± 1.2 19.3 ± 1.0
5%KO  18.1 ± 1.2 20.7 ± 1.3 20.9 ± 1.2 21.5 ± 1.4 22.6 ± 1.6 22.3 ± 1.8 22.1 ± 1.7 21.5 ± 1.5 21.8 ± 1.2 21.2 ± 1.4 21.0 ± 1.6 22.1 ± 2.5 20.9 ± 1.7 20.9 ± 2.5
Females
Control  13.5 ± 0.6 14.9 ± 0.4 15.3 ± 0.8 15.5 ± 0.9 16.4 ± 1.3 15.9 ± 1.4 15.2 ± 1.8 15.1 ± 1.7 15.0 ± 1.5 15.5 ± 2.0 15.4 ± 2.1 14.1 ± 1.4 13.7 ± 0.8 13.6 ± 0.7
1.7%KO  12.3 ± 0.7 14.7 ± 0.7 15.3 ± 1.0 16.3 ± 1.9 15.7 ± 1.0 15.3 ± 1.4 16.5 ± 2.6 16.7 ± 3.3 14.5 ± 0.3 15.9 ± 1.4 15.8 ± 2.6 14.7 ± 0.4 14.8 ± 1.9 13.5 ± 1.1
3.3%KO  12.9 ± 1.0 13.9 ± 1.4 14.3 ± 1.2 14.9 ± 1.0 15.2 ± 1.0 14.5 ± 0.7 14.2 ± 0.7 14.4 ± 0.4 14.1 ± 0.7 14.6 ± 0.7 13.9 ± 0.8 14.7 ± 1.3 12.9 ± 0.5 13.6 ± 0.6
16.4 ± 1.0 16.0 ± 1.2 15.7 ± 1.7 15.1 ± 1.4 14.3 ± 1.3 14.9 ± 1.1 15.3 ± 1.7 15.0 ± 1.3 13.9 ± 0.7 13.2 ± 0.7
 food consumption of animals per cage by the number of animals in each cage (animals housed 2 or 3 per cage). All values are means of 45%KO  13.0 ± 0.7 14.8 ± 1.0 15.3 ± 1.1 15.7 ± 1.3
KO: krill oil. The values given are calculated by dividing the weekly
cages  ± SD.
Signiﬁcantly different from control:
b = p < 0.01
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Table 3
Krill  oil intake by dietary administration (mg/kg body weight/day).
1.7% KO 3.3% KO 5% KO
Males 1044 ± 272 1929 ± 491 2999 ± 752
Females 1256 ± 253 2346 ± 424 3532 ± 710
KO: krill oil. The data represent average krill oil intake throughout the
1
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m3-week study period and was calculated by using weekly data of body
eights and food consumption.
Water consumption. Visual inspection of water bottles
evealed no intergroup differences throughout the treat-
ent  period.
Ophthalmoscopy. There were no ﬁndings that were con-
idered  to be due to treatment with krill oil.
Functional observation battery parameters. There were noifferences in the functional observation battery parame-
ers  that were considered to be due to the consumption
f diets containing krill oil. A reduced distance between
anding foot splay was noted to be signiﬁcantly lower in
ig. 2. Functional observation parameters include the distance between landing
easurements in male (C) and (D) rats. All data are mean ± SD (n = 10). (*) Signiﬁports 1 (2014) 764–776 769
females  fed diet containing 1.7% krill oil compared to con-
trol  (Fig. 2B). Due to the very small magnitude of the
difference and the absence of any differences in the higher
dose  level or in the male groups (Fig. 2A) this was con-
sidered not to be related to treatment. There were no
differences in overall motor activity that were attributed
to the consumption of diets containing krill oil (Fig. 2C and
D).  However, when individual 5-min intervals were com-
pared  to the control group, then activity was noted to be
signiﬁcantly lower in males fed 5% krill oil at the 36–40 min
interval  of the 60-min period (data not shown). However,
due to the absence of any signiﬁcant changes in the other
11  intervals for the males and no signiﬁcant changes in any
intervals  for females, in addition to the lack of any in-life
clinical observations suggesting subdued behaviour and/or
lethargy  etc., the toxicological signiﬁcance of these ﬁndings
remain  unclear.
Haematology and coagulation. There were no differ-
ences in coagulation parameters that were considered to
be  due to the consumption of diets containing krill oil
 foot splay in male (A) and female (B) animals, as well as motor activity
cantly different from control group (p < 0.05).
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Table  4
Haematology and coagulation.
Control 1.7% KO 3.3% KO 5% KO
Males
No. of animals 6 10 7 10
Haemoglobin  (g/dL) 15.7 ± 0.8 15.5 ± 0.6 15.2 ± 0.5 15.3 ± 0.7
Red  blood cells (×1012/L) 8.55 ± 0.70 8.40 ± 0.37 8.20 ± 0.28 8.57 ± 0.46
Haematocrit (L/L) 0.43 ± 0.02 0.43 ± 0.02 0.42 ± 0.01 0.43 ± 0.02
Mean  cell haemoglobin (pg) 18.5  ± 1.5 18.4 ± 0.7 18.6 ± 0.7 17.8 ± 0.8
Mean  cell volume (fL) 50.6 ± 3.2 50.9 ± 1.9 51.1 ± 1.4 50.0 ± 1.5
Mean  cell haemoblobin concentration (g/dL) 36.5 ± 0.9 36.2 ± 1.0 36.4 ± 0.5 35.7 ± 0.9
Reticulocytes (%) 1.8 ± 0.3 2.1 ± 0.3 2.0 ± 0.2 1.9 ± 0.2
White  blood cells (×109/L) 6.41 ± 1.27 6.75 ± 1.56 5.87 ± 1.21 6.01 ± 1.38
Neutrophils (×109/L) 1.12 ± 0.37 1.17 ± 0.41 0.84 ± 0.17 0.85 ± 0.31
Lymphocytes (×109/L) 5.00 ± 1.04 5.24 ± 1.43 4.77 ± 1.04 4.88 ± 1.11
Monocytes (×109/L) 0.10 ± 0.02 0.13 ± 0.06 0.10 ± 0.03 0.11 ± 0.04
Eosinophils (×109/L) 0.14 ± 0.05 0.14 ± 0.03 0.11 ± 0.04 0.12 ± 0.03
Basosophils (×109/L) 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.00
Large  unclassiﬁed cells (×109/L) 0.04 ± 0.01 0.05 ± 0.03 0.05 ± 0.02 0.03 ± 0.02
Platelets  (×109/L) 747 ± 119 672 ± 57 699 ± 66 674 ± 110
Prothrombin time (s) 15 ± 1 (8) 15 ± 1 15 ± 1 (10) 15 ± 1 (9)
Activated partial thromboplastin time (s) 20 ± 2 (8) 22 ± 2 22 ± 3 (9) 22 ± 2 (8)
Females
No.  of animals 9 9 8 8
Haemoglobin  (g/dL) 15.0 ± 0.6 14.9 ± 0.4 14.6 ± 0.6 15.0 ± 0.4
Red  blood cells (×1012/L) 8.06 ± 0.45 7.65 ± 0.31 7.87 ± 0.46 7.84 ± 0.26
Haematocritt (L/L) 0.42 ± 0.02 0.41 ± 0.02 0.40 ± 0.02 0.42 ± 0.01
Mean  cell haemoglobin (pg) 18.6 ± 0.8 19.4 ± 0.7a 18.5 ± 0.6 19.2 ± 0.9
Mean  cell volume (fL) 51.5 ± 1.8 53.1 ± 1.8a 51.3 ± 1.1 53.3 ± 1a
Mean cell haemoblobin concentration (g/dL) 36.1 ± 0.9 36.6 ± 0.7 36.1 ± 0.8 36 ± 1
Reticulocytes (%) 2.6 ± 0.5 2.2 ± 0.3 2.6 ± 0.3 2.6 ± 0.7
White  blood cells (×109/L) 4.54 ± 0.56 4.68 ± 0.95 4.93 ± 1.21 4.75 ± 1.25
Neutrophils (×109/L) 0.62 ± 0.2 0.66 ± 0.11 0.71 ± 0.25 0.75 ± 0.46
Lymphocytes (×109/L) 3.71 ± 0.65 3.77 ± 0.83 3.99 ± 1.05 3.78 ± 0.86
Monocytes (×109/L) 0.08 ± 0.02 0.10 ± 0.05 0.10 ± 0.05 0.10 ± 0.04
Eosinophils (×109/L) 0.09 ± 0.03 0.10 ± 0.02 0.07 ± 0.02 0.10 ± 0.05
Basophils (×109/L) 0.01 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
Large  unclassiﬁed cells (×109/L) 0.03 ± 0.02 0.03 ± 0.02 0.04 ± 0.02 0.02 ± 0.01
Platelets  (×109/L) 692 ± 108 749 ± 100 679 ± 100 663 ± 166
Prothrombin time (s) 15 ± 1 14 ± 1 (10) 15 ± 1 15 ± 1
Activated partial thromboplastin time (s) 21 ± 2 (8) 21 ± 2 (10) 23 ± 3 21 ± 3 (7)
KO: krill oil. All values are means ± SD for 6–10 animals, with the exceptions described above in parenthesis.
Signiﬁcantly different from control:
a p < 0.05.
(Table 4). However, while male mean cell haemoglobin
values were not changed in the krill oil groups com-
pared to the control group, this parameter was signiﬁcantly
increased in the female 1.7% krill oil group. Furthermore, in
females  given 1.7% and 5% krill oil, there was also a signif-
icant  increase in mean cell volume, whereas male values
remained unchanged in all groups. No other haematology
parameters were affected.
Clinical  chemistry. Signiﬁcantly increased plasma
triglyceride levels were observed in female rats receiving
1.7%  krill oil (Table 5). Increases in blood total protein in
animals  treated with krill oil, achieving statistical signiﬁ-
cance  against control, were noted in both sexes. Globulin
levels were also statistically signiﬁcantly increased in
both  males and females fed diets containing 5% krill oil.
This  change was reﬂected in the albumin–globulin ratio
which  was reduced, achieving statistical signiﬁcance in
males  only. Other minor differences achieving statistical
signiﬁcance in clinical chemistry parameters were noted
in  both males treated at 3.3% krill oil (decreased urea
volume and cholesterol) and 5% (increased total proteinand  globulin and decreased globulin/albumin). In females,
signiﬁcant changes were seen in all krill oil groups: 1.7%
(increased triglycerides, total protein and albumin), 3.3%
(increased lactate dehydrogenase) and 5% (increased
lactate dehydrogenase, total protein and globulin). As the
differences had no supporting histological evidence, and
due  to the small magnitude of the difference and lack of
any  dose response, their toxicological signiﬁcance was
considered to be minimal.
Urinalysis.  There were no differences in urinalysis
parameters that were considered to be due to the con-
sumption of diets containing krill oil (Table 6). An isolated
incidence of statistical signiﬁcance was noted in urinary
pH  in males treated with diets containing 5% krill oil
in  comparison to control. As this was an isolated inci-
dence and did not show any dose response, the difference
was  not considered to be of toxicological signiﬁcance.
Due to the small volume of several female samples,
an accurate comparison could not be made against the
control  groups, although no numerical differences were
noted.
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Table 5
Clinical chemistry at termination.
Control 1.7% KO 3.3% KO 5% KO
Males
No. of animals 8 10 10 10
Alkaline  phosphatase (iu/L) 97 ± 17 109 ± 40 92 ± 17 114 ± 16
Alanine  aminotransferase (iu/L) 23 ± 5 25 ± 4 25 ± 6 24 ± 4
Aspartate aminotransferase (iu/L) 60  ± 8 63 ± 13 59 ± 7 55 ± 8
Lactate  dehydrogenase (iu/L) 102 ± 27 126 ± 152 97 ± 34 117 ± 37
Urea  (mmol/L) 5.7 ± 0.3 5.8 ± 0.5 5.2 ± 0.3a 6.1 ± 0.5
Glucose  (mmol/L) 11.94 ± 1.57 10.81 ± 1.25 11.21 ± 1.08 11.34 ± 2.10
Total  bilirubin (mol/L) 1.7 ± 0.0 1.7 ± 0.0 1.7 ± 0.0 1.7 ± 0.0
Cholesterol (mmol/L) 1.9 ± 0.2 1.7 ± 0.3 1.5 ± 0.1b 2.1 ± 1.8
Triglycerides (mmol/L) 2.53 ± 0.60 2.31 ± 1.00 1.9 ± 0.32 2.51 ± 1.87
Total  protein (g/L) 66 ± 2 67 ± 3 68 ± 2 69 ± 3a
Albumin (g/L) 42 ± 1 43 ± 2 43 ± 2 41 ± 4
Globulin (g/L) 24 ± 2 25 ± 2 25 ± 2 29 ± 3c
Albumin:globulin ratio 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.2 1.5 ± 0.2b
Sodium (mmol/L) 142 ± 3 142 ± 2 141 ± 1 143 ± 2
Potassium (mmol/L) 4.2 ± 0.2 4.1 ± 0.3 4.1 ± 0.2 4.2 ± 0.2
Phosphate (mmol/L) 1.24 ± 0.27 1.32 ± 0.19 1.33 ± 0.09 1.35 ± 0.15
Calcium  (mmol/L) 2.68 ± 0.04 2.68 ± 0.07 2.66 ± 0.03 2.69 ± 0.05
Females
No.  of animals 10 10 10 10
Alkaline  phosphatase (iu/L) 111 ± 76 58 ± 23 63 ± 32 56 ± 20
Alanine aminotransferase (iu/L) 19 ± 4 19 ± 2 25 ± 13 23 ± 4
Aspartate aminotransferase (iu/L) 60 ± 8 55 ± 6 57 ± 7 59 ± 9
Lactate  dehydrogenase (iu/L) 73 ± 10 80 ± 22 105 ± 33a 162 ± 122c
Urea (mmol/L) 7 ± 0.9 6.4 ± 1.0 6.3 ± 0.7 6.5 ± 0.6
Glucose  (mmol/L) 10.75 ± 1.48 10.06 ± 0.84 9.93 ± 1.32 9.91 ± 1.23
Total  bilirubin (mol/L) 1.9 ± 0.5 1.7 ± 0.0 1.7 ± 0.0 1.7 ± 0.0
Cholesterol (mmol/L) 1.2 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.4
Triglycerides (mmol/L) 1.39 ± 0.78 2.58 ± 1.65a 1.76 ± 0.87 1.71 ± 1.56
Total  protein (g/L) 69 ± 3 73 ± 4b 71 ± 3 73 ± 3b
Albumin (g/L) 49 ± 3 53 ± 3b 52 ± 3 51 ± 3
Globulin (g/L) 19 ± 2 20 ± 2 20 ± 1 22 ± 2c
Albumin:globulin ratio 2.6 ± 0.3 2.7 ± 0.3 2.6 ± 0.2 2.3 ± 0.3
Sodium  (mmol/L) 141 ± 1 142 ± 2 141 ± 1 142 ± 2
Potassium (mmol/L) 3.6 ± 0.2 3.8 ± 0.2 3.6 ± 0.2 3.8 ± 0.3
Phosphate (mmol/L) 1.12 ± 0.24 1.01 ± 0.15 1.11 ± 0.12 1.22 ± 0.12
Calcium  (mmol/L) 2.68 ± 0.04 2.73 ± 0.08 2.70 ± 0.08 2.68 ± 0.07
KO: krill oil. All values are means ± SD for 8–10 animals.
Signiﬁcantly different from control:
c
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Sa p < 0.05,
b p < 0.01,
c p < 0.001
Organ weight. Organ weights are presented as per-
entage of terminal body weight (Table 7) and as
bsolute weights (Table 8). The only signiﬁcant ﬁnding
as  a decreased absolute heart weight in male (3.3%
able 6
rinalysis at week 13.
Control 1.7% KO 
Males
Urine speciﬁc gravity 1.055 ± 0.012 1.047 ±
Urine  volume (mL) 0.7 ± 0.5 0.6 ±
pH  8.0 ± 1.1 7.8 ±
Females
Urine speciﬁc gravity 1.058 ± (−) 1.043 ±
Urine  volume (mL) 0.1 ± 0.0 0.3 ±
pH  6.6 ± 0.5 7.1 ±
O: krill oil. All values are means ± SD. The number of samples in males was: urin
o  the small number of several female samples (urine speciﬁc gravity: n = 1–3; ur
ade  against the control groups, although no numerical differences were noted.
igniﬁcantly different from control:
b p < 0.01.krill  oil) and female (all krill oil groups), compared to
control animals. However, after adjustment for body
weight, no signiﬁcant changes in organs weights were
observed.
3.3% KO 5% KO
 0.015 1.057 ± 0.012 1.053 ± 0.013
 0.5 0.3 ± 0.2 0.7 ± 0.6
 1.0 7.4 ± 0.9 6.8 ± 0.3b
 0.020 1.072 ± (−) 1.044 ± (−)
 0.3 0.1 ± 0.1 0.2 ± 0.1
 0.5 6.5 ± 0.0 6.7 ± 0.4
e speciﬁc gravity: n = 6–9; urine volume: n = 9–10; pH: n = 9–10. (−): Due
ine volume: n = 5–10; pH: n = 2–5), an accurate comparison could not be
772 B. Robertson et al. / Toxicology Reports 1 (2014) 764–776
Table  7
Relative organ weights (% of body weight).
Control 1.7% KO 3.3% KO 5% KO
Males
No. of animals 9 10 10 10
Adrenals  0.013 ± 0.002 0.014 ± 0.001 0.014 ± 0.001 (8) 0.012 ± 0.002
Brain  0.43 ± 0.04 0.42 ± 0.03 0.46 ± 0.04 0.42 ± 0.03
Epididymides 0.29 ± 0.05 0.28 ± 0.04 0.29 ± 0.06 0.27 ± 0.04 (9)
Heart  0.29 ± 0.02 0.26 ± 0.02 0.26 ± 0.02 0.27 ± 0.02
Kidneys  0.61 ± 0.02 0.61 ± 0.09 0.62 ± 0.04 0.62 ± 0.11
Liver  3.3 ± 0.2 3.4 ± 0.4 3.5 ± 0.2 3.7 ± 0.3
Lung  0.38 ± 0.04 0.39 ± 0.04 0.4 ± 0.07 0.42 ± 0.08
Pituitary  0.0018 ± 0.0003 0.0018 ± 0.0003 (7) 0.0022 ± 0.0006 0.0020 ± 0.0002
Prostate  0.10 ± 0.02 0.11 ± 0.03 0.11 ± 0.02 0.10 ± 0.02
Spleen  0.15 ± 0.02 0.15 ± 0.01 0.15 ± 0.02 0.15 ± 0.01
Testes  0.76 ± 0.09 0.72 ± 0.10 0.75 ± 0.15 0.70 ± 0.06 (9)
Thymus  0.11 ± 0.02 0.11 ± 0.01 0.10 ± 0.02 0.10 ± 0.02
Thyroid  0.0057 ± 0.0012 0.0058 ± 0.0008 0.0528 ± 0.0013 (9) 0.0067 ± 0.0017
Females
No.  of animals 10 10 10 10
Adrenals  0.029 ± 0.007 0.029 ± 0.005 0.029 ± 0.005 0.029 ± 0.005 (9)
Brain  0.70 ± 0.09 0.72 ± 0.06 0.75 ± 0.04 0.75 ± 0.06
Heart  0.34 ± 0.04 0.32 ± 0.01 0.35 ± 0.03 0.32 ± 0.03
Kidneys  0.66 ± 0.08 0.65 ± 0.05 0.67 ± 0.07 0.67 ± 0.03
Liver  3.2 ± 0.3 3.4 ± 0.3 3.5 ± 0.4 3.6 ± 0.4
Lung  0.54 ± 0.09 0.52 ± 0.07 0.54 ± 0.08 0.53 ± 0.07
Ovaries  0.042 ± 0.008 0.040 ± 0.005 0.041 ± 0.001 0.044 ± 0.012
Pituitary  0.0045 ± 0.0007 0.0045 ± 0.0007 0.0050 ± 0.0010 0.0050 ± 0.0008 (9)
Spleen  0.21 ± 0.02 0.23 ± 0.02 0.24 ± 0.02 0.24 ± 0.03
Thymus  0.17 ± 0.04 0.15 ± 0.03 0.15 ± 0.03 0.14 ± 0.03
Thyroid  0.0075 ± 0.0016 0.0093 ± 0.0015 0.0078 ± 0.0016 0.0080 ± 0.0012 (9)
Uterus  0.25 ± 0.16 0.26 ± 0.09 0.26 ± 0.11 0.25 ± 0.07
 krill oil
ogetherKO: krill oil. No signiﬁcant changes were observed between control and
exceptions  described above in parenthesis. Paired organs were weighed t
Macroscopic ﬁndings. Prominent lobulation of the liver
was  observed in 6/10, 7/10 and 7/10 males receiving 1.7,
3.3  and 5% krill oil respectively, and in 1/10 females receiv-
ing  1.7% krill oil. Hepatic lobulation in a normal liver is
only  seen or deﬁned on microscopic evaluation. However, if
there  is a microscopic ﬁnding which follows a pattern (por-
tal,  periportal, centrilobular, etc.) the lobular appearance of
the  liver becomes prominent and can be seen macroscopi-
cally.
Microscopic ﬁndings. Periportal microvesicular hepato-
cyte vacuolation (minimal to mild) was observed in 5/10
males  which received 5% krill oil (Table 9). This correlated
with the ﬁndings of prominent liver lobulation observed
at  necropsy. In males which received 5% krill oil, the inci-
dence  of this ﬁnding was statistically signiﬁcant when
compared with controls (p < 0.05). The hepatocyte vacuo-
lation  was not associated with hepatocellular necrosis or
inﬂammation, and there were no clinical pathology ﬁnd-
ings  suggesting liver impairment, therefore, this ﬁnding
was  considered adaptive and non-adverse. There was no
hepatocyte vacuolation observed in animals receiving 1.7%
or  3.3% krill oil.
3.2.  Genotoxicity studyDose-ﬁnding  toxicity test for Ames assay. With krill oil
doses  ranging from 17 to 5000 g per plate, no increased
bacterial numbers (S. typhimurium strain TA100 ± S9 mix)
of  revertant colonies over those occurring spontaneously groups (p < 0.05). All values are means ± SD for 9–10 animals, with the
.
could be observed (Table 10). Thus, no toxicity of krill oil to
bacteria  became evident. Some precipitation was  observed
at  the two highest krill oil concentrations tested.
Ames assay. The Ames assay was  performed on 5 dif-
ferent bacterial strains with either vehicle or 6 different
krill oil doses (up to 5000 g per plate). The assay revealed
that the average numbers of his+ and trp+ revertant colonies
were not increased using either the ‘Direct plate incorpo-
ration method’ (Table 11) or the ‘Pre-incubation method’
(Table 12). Therefore, there was  no evidence of mutagenic
activity of krill oil to any of the strains tested.
4. Discussion
The results of the 13-week toxicity study in rats demon-
strate a lack of toxicologically signiﬁcant adverse effects
following oral administration of krill oil at doses up to 5%
inclusion  levels in the diet. Daily administration of krill oil
at  inclusion levels up to 5% for at least 13 weeks resulted
in  in-life clinical observations which included abnormally
coloured faeces (pale and/or yellow). This was considered
a  result of the manufactured diet which itself ranged in
colour  from pale white through yellow to red (due to the
astaxanthin content in krill oil). There were no deaths noted
over  the duration of treatment with krill oil. And no dif-
ferences were noted in body weight or food consumption.
Additionally there were no differences noted in the func-
tional  observation parameters in either sex which could be
attributed  to treatment with krill oil.
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Table 8
Absolute organ weights (g).
Control 1.7% KO 3.3% KO 5% KO
Males
No. of animals 9 10 10 10
Final  body weight 481 ± 51 479 ± 38 450 ± 51 475 ± 46
Adrenals 0.062 ± 0.007 0.065 ± 0.005 0.060 ± 0.004 (8) 0.059  ± 0.011
Brain  2.05 ± 0.05 2.02 ± 0.06 2.03 ± 0.08 2.00 ± 0.11
Epididymides 1.36 ± 0.17 1.33 ± 0.19 1.31 ± 0.17 1.30 ± 0.15 (9)
Heart  1.36 ± 0.13 1.26 ± 0.12 1.18 ± 0.14b 1.26 ± 0.11
Kidneys  2.95 ± 0.34 2.89 ± 0.36 2.78 ± 0.32 2.90 ± 0.33
Liver  15.96 ± 1.95 16.12 ± 2.38 15.85 ± 2.23 17.52 ± 1.96
Lung  1.82 ± 0.17 1.87 ± 0.30 1.81 ± 0.24 2.01 ± 0.38
Pituitary  0.009 ± 0.001 0.009 ± 0.001 (7) 0.010 ± 0.003 0.009 ± 0.001
Prostate  0.49 ± 0.1 0.55 ± 0.14 0.50 ± 0.11 0.49 ± 0.08
Spleen  0.69 ± 0.05 0.73 ± 0.06 0.69 ± 0.09 0.71 ± 0.06
Testes  3.62 ± 0.27 3.44 ± 0.43 3.34 ± 0.52 3.36 ± 0.18 (9)
Thymus  0.54 ± 0.09 0.54 ± 0.09 0.47 ± 0.08 0.47 ± 0.09
Thyroid  0.027 ± 0.005 0.028 ± 0.004 0.024 ± 0.006 (9) 0.032 ± 0.009
Females
No.  of animals 10 10 10 10
Final  body weight 263 ± 38 249 ± 17 240 ± 9 251 ± 25
Adrenals 0.076 ± 0.016 0.072 ± 0.012 0.070 ± 0.012 0.074 ± 0.009 (9)
Brain  1.82 ± 0.08 1.77 ± 0.04 1.80 ± 0.06 1.86 ± 0.08
Heart  0.90 ± 0.12 0.79 ± 0.05b 0.83 ± 0.06a 0.80 ± 0.06b
Kidneys 1.71 ± 0.2 1.61 ± 0.13 1.60 ± 0.16 1.68 ± 0.15
Liver  8.43 ± 1.01 8.44 ± 0.85 8.46 ± 1.14 9.05 ± 1.04
Lung  1.40 ± 0.24 1.30 ± 0.18 1.29 ± 0.17 1.34 ± 0.24
Ovaries  0.11 ± 0.02 0.10 ± 0.01 0.10 ± 0.01 0.11 ± 0.03
Pituitary  0.012 ± 0.002 0.011 ± 0.002 0.012 ± 0.003 0.012 ± 0.002 (9)
Spleen  0.55 ± 0.08 0.57 ± 0.07 0.57 ± 0.05 0.59 ± 0.08
Thymus  0.44 ± 0.12 0.38 ± 0.09 0.36 ± 0.09 0.35 ± 0.05
Thyroid  0.020 ± 0.005 0.023 ± 0.005 0.019 ± 0.004 0.020 ± 0.003 (9)
Uterus  0.65 ± 0.44 0.63 ± 0.20 0.63 ± 0.25 0.63 ± 0.21
KO: krill oil. All values are means ± SD for 9–10 animals, with the exceptions detailed above in parenthesis. Paired organs were weighed together.
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be  effective in decreasing liver fat in two different obesity
models, where the animals had abnormally high hepaticigniﬁcantly different from control:
a p < 0.05,
b p < 0.01.
Several differences in both haematology and clinical
hemistry values were noted in the krill oil-treated groups
hen  compared to control; however the ﬁndings were
onsidered to be of no toxicological signiﬁcance since the
hanges  were small, were not dose-dependent, were not
bserved  in both sexes, and were not related to histopatho-
ogical changes.
Periportal microvesicular hepatocyte vacuolation was
resent  only in animals fed the highest krill oil dose of 5%.
he  microvesicular vacuolation might have been caused by
ccumulation of triglycerides (hepatic lipidosis) due to the
igh  dose of lipids given [25]. This is commonly found to be
 compensatory, transient response that has been observed
able 9
istological ﬁndings.
Males Females
Control 5% KO Control 5% KO
Liver (10) (10) (10) (10)
Microvesicular,  periportal hepatocyte vacuolation
Minimal 0 4 0 0
Mild  0 1 0 0
Total  incidence 0 5* 0 0
O: krill oil. There was no hepatocyte vacuolation observed in animals
eceiving 1.7% or 3.3% krill oil.
* Signiﬁcantly different from control (p < 0.05).previously [26]. Additionally, hepatic lipidosis can occur as
the  result of excessive delivery of free fatty acids either
from the gut or from adipose tissue [27]. However, there
was  no microvesicular vacuolation with lower doses of
krill  oil supplementation, and in none of the groups were
other  indications of hepatic dysfunction observed. More-
over,  krill oil at a level of 2.5% in the diet has been shown tolipid  levels [28,29].
Table 10
Dose-ﬁnding toxicity test.
Krill oil dose per plate
(g)
Mean revertants per plate
Without metabolic
activation (−S9 mix)
With metabolic
activation (+S9 mix)
0 65 68
17 51 77
50 82 75
167 50 90
500 66 54
1667 55p 90p
5000 60p 75p
p = Precipitate.
Strain used: S. typhimurium TA100.
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Table 11
First  mutation assay (direct plate incorporation method).
Treatment (g/plate) Revertants per plate
TA1535 TA1537 TA98 TA100 WP2uvrA
−S9 +S9 −S9 +S9 −S9 +S9 −S9 +S9 −S9 +S9
0 17.0 ± 6.9 20.3 ± 6.8 9.0 ± 3.6 13.3 ± 2.3 35.0 ± 3.0 51.0 ± 6.1 92.0 ± 6.9 110.3 ± 21.5 6.3 ± 2.5 6.0 ± 5.6
17  19.0 ± 10.6 18.3 ± 7.4 12.3 ± 2.5 16.3 ± 5.1 34.0 ± 1.7 54.7 ± 8.7 102.0 ± 5.7 108.3 ± 2.9 6.7 ± 5.0 5.7 ± 1.2
50  17.3 ± 4.5 21.0 ± 4.2 11.7 ± 5.0 14.0 ± 3.6 26.3 ± 9.7 46.7 ± 3.1 104.0 ± 17.0 110.0 ± 8.7 8.0 ± 2.6 8.3 ± 1.2
167  11.0 ± 5.6 24.3  ± 3.8 14.7  ± 3.2 16.3 ± 3.5 37.3 ± 10.3 50.7 ± 6.5 97.7 ± 3.5 118.3 ± 13.3 9.3 ± 5.5 6.7 ± 2.1
500  18.0 ± 7.9 20.3 ± 3.1 11.3 ± 4.0 14.3 ± 3.2 31.7 ± 3.5 48.5 ± 12.0 97.3 ± 9.6 103.3 ± 9.6 9.0 ± 2.6 2.7 ± 2.1
1667  13.3 ± 3.5p 20.3 ± 3.8p 13.7 ± 8.3p 14.7 ± 2.3p 35.0 ± 8.7p 50.7 ± 4.5p 102.7 ± 12.2p 118.7 ± 10.8p 5.0 ± 4.6p 5.3 ± 1.2p
5000 12.7 ± 3.8p 21.0 ± 7.2p 12.3 ± 0.6p 13.3 ± 3.2p 35.0 ± 13.5p 59.7 ± 7.8p 77.0 ± 32.9p 115.7 ± 1.5p 4.7 ± 2.5p 12.7 ± 0.6p
Pos. control 474.3 ± 4.0 477.0 ± 38.6 8695.7 ± 582.8 416.3 ± 40.5 838.0 ± 34.6 544.3 ± 27.4 1129.7 ± 38.9 841.0 ± 10.1 96.3 ± 18.6 448.7 ± 41.8
p Precipitate.
All colony numbers of revertants are means of 3 plates ± SD.
Positive controls for each strain were as follows: Strains with S9 activation: 2 g/plate 2-aminoanthracene (TA1535 and TA1537), 0.5 g/plate (TA98 and TA100) and 20 g/plate (WP2uvrA). Strains without S9
activation: 1 g/plate sodium azide (TA1535 and TA100), 2 g/plate N-ethyl-N-nitro-N-nitrosoguanidine (WP2uvrA), 1 g/plate 2-nitroﬂuorene (TA98) and 80 g/plate 9-aminoacridine (TA1537).
Table 12
Second mutation assay (pre-incubation method) TDENDOFDOCTD.
Treatment Revertants per plate (g/plate)
TA1535 TA1537 TA98 TA100 WP2uvrA
−S9 +S9 −S9 +S9 −S9 +S9 −S9 +S9 −S9 +S9
0 11.0 ± 2.0 17.0 ± 3.6 11.0 ± 2.0 9.3 ± 2.5 27.7 ± 4.7 39.3 ± 9.8 87.3 ± 17.2 98.7 ± 0.6 2.3 ± 1.5 8.0 ± 5.3
17  14.3 ± 4.6 14.0 ± 2.6 8.7 ± 2.9 16.0 ± 1.0 30.3 ± 2.1 41.0 ± 6.1 92.0 ± 6.2 99.0 ± 7.0 5.0 ± 1.0 5.7 ± 0.6
50  17.0 ± 1.0 15.7 ± 2.3 9.7 ± 2.5 12.7 ± 2.5 34.7 ± 3.8 42.0 ± 14.7 91.7 ± 7.2 98.7 ± 11.1 2.7 ± 2.1 7.0 ± 2.0
167  9.0 ± 3.0 17.3 ± 3.2 11.7 ± 3.8 12.7 ± 3.1 31.0 ± 1.7 46.0 ± 8.5 95.3 ± 22.4 98.7 ± 12.1 5.7 ± 1.2 7.0 ± 3.0
500  7.7 ± 2.3 17.0 ± 5.3 11.7 ± 1.5 16.3 ± 5.5 34.3 ± 7.2 43.7 ± 11.6 89.7 ± 5.5 94.0 ± 8.7 1.3 ± 1.2 6.0 ± 3.6
1667  12.3 ± 3.2 22.3 ± 7.5 9.0 ± 0.0 14.7 ± 3.2 33.0 ± 7.2 51.7 ± 2.1 93.0 ± 6.1 108.3 ± 18.5 4.0 ± 3.0 11.3 ± 3.2
5000  10.3 ± 3.1p 13.0 ± 1.7p 13.7 ± 5.8p 15.7 ± 2.3p 31.0 ± 1.7p 51.0 ± 6.1p 89.3 ± 4.6p 85.3 ± 11.0p 7.0 ± 1.7p 9.0 ± 2.0p
Pos. control 528.0 ± 5.6 299.3 ± 28.6 5014.3 ± 432.3 204.7 ± 17.0 622.0 ± 55.0 302.0 ± 22.6 1260.3 ± 25.7 872.3 ± 64.7 157.7 ± 22.0 515.3 ± 39.7
p Precipitate.
All colony numbers of revertants are means of 3 plates ± SD.
Positive controls for each strain were as follows: Strains with S9 activation: 2 g/plate 2-aminoanthracene (TA1535 and TA1537), 0.5 g/plate (TA98 and TA100) and 20 g/plate (WP2uvrA). Strains without S9
activation:  1 g/plate sodium azide (TA1535 and TA100), 2 g/plate N-ethyl-N-nitro-N-nitrosoguanidine (WP2uvrA), 1 g/plate 2-nitroﬂuorene (TA98) and 80 g/plate 9-aminoacridine (TA1537).
Result Evaluation: For S. typhimurium strains TA1535, TA1537, and TA98 and for E. coli WP2uvrA,  at least a doubling of the mean concurrent vehicle control value was required before mutagenic activity was
suspected (in addition, an absolute mean plate count of at least 20 colonies per plate was  required). For S. typhimurium strain TA100, a 1.5-fold increase over the control value was considered indicative of a
mutagenic effect.
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There was no signiﬁcant change in plasma triglyceri-
es levels in animals fed diets containing krill oil, except
or  the females receiving the lowest dose of krill oil (1.7%).
his  observation could be explained by variability due to
he  non-fasted state of the animals. Given that the effects
f  the 13-week toxicity study were not adverse in nature,
he  no-observed-adverse-effect-level (NOAEL) for the con-
itions  of this study was considered to be 5% krill oil
equating to 2999 mg  krill oil/kg body weight/day for males
nd  3532 mg  krill oil/kg body weight/day for females). The
afety  of krill oil was further supported in a mutagenicity
est, which showed that this substance was not mutagenic
hen tested in ethanol up to and beyond the limit of its sol-
bility  (predetermined maximum of 5000 g) in the Ames
est  system with S. typhimurium TA1535, TA1537, TA98 and
A100  and E. coli strain WP2uvrA.  The results in the cur-
ent  paper are based on a subacute toxicity study in rats.
ecause krill oil is recommended for lifetime consumption,
uture experiments should also address the toxicological
otential of krill oil in a chronic long-term study. More-
ver, a teratogenicity study as well as a micronucleus
est have been performed in a separate study without
howing any negative effects of krill oil, thereby further
onﬁrming the safety of krill oil consumption (data to be
ublished).
.  Conclusions
In  summary, the dietary administration of krill oil at
nclusion levels up to 5% to rats for at least 13 weeks
emonstrated no adverse toxicological in-life, haema-
ology and/or blood chemistry effects. Findings were
estricted to periportal microvesicular hepatocyte vacuo-
ation  in male animal fed diets containing 5% krill oil with
o  correlated increase in organ weight.
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